Darae's insight pays off — pain drug developer RudaCure selected for
首尔-type private investment-linked technology commercialization support program
RudaCure Inc. (CEO Yongho Kim), a company specializing in developing treatments for 感觉障碍, recommended by 首尔-type TIPS operator Darae战略事业化中心 Co., Ltd. (CEOs Bae Sun-gu and Kim Jeong-guk), was announced on the 30th as having been selected for the 首尔-type Private Investment-linked Technology Commercialization Support Program (首尔-type TIPS).
The 首尔-type Private Investment-linked Technology Commercialization Support Program is a program in which 首尔 Metropolitan City and the 首尔产业振兴院 (sba) leverage the 初创企业 discovery and investment capabilities of private operators to support promising technology 初创企业. Through this selection, RudaCure has secured up to KRW 400 million in R&D funding over two years.
RudaCure plans to use the secured R&D funding to advance the development stage of its non-narcotic 慢性疼痛治疗药 管线.
Bae Sun-gu, CEO of Darae战略事业化中心—RudaCure's investor and 首尔-type TIPS operator—said, "We recommended RudaCure based on a high evaluation of the technological innovativeness of its 药物开发 for 感觉障碍 diseases," and added, "As a 首尔-type TIPS operator, we will more actively expand the infrastructure to match and support R&D funding without equity dilution for promising 初创企业s."
RudaCure CEO Yongho Kim stated, "Building on this 首尔-type TIPS selection, we will focus on increasing company value by strengthening our non-narcotic 慢性疼痛治疗药 alongside our main 管线, the 干眼症治疗药 ROC001."
Meanwhile, Darae战略事业化中心 is active as both a 中小企业部 TIPS operator and a 首尔-type TIPS operator, and plans to continuously expand strategic support for portfolio companies with excellent technology.
전자신문: https://www.etnews.com/20231103000235